Meeting
2021 ASCO Annual Meeting
Prognostic value of SUVmax on FDG-PET/CT before and after stereotactic body radiotherapy (SBRT) on recurrence and survival in early-stage non-small cell lung cancer (NSCLC).
Authors
Saarang Deshpande
Case Western Reserve University School of Medicine, Cleveland, OH
Saarang Deshpande , Tarun Kanti Podder , Yuxia Zhang , Yiran Zheng , William Grubb , Michael Kharouta , Philip Aaron Linden , Tithi Biswas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Local-Regional Non–Small Cell Lung Cancer
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8539)
DOI
10.1200/JCO.2021.39.15_suppl.8539
Abstract #
8539
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.
First Author: Joe Y. Chang
Poster
2013 ASCO Annual Meeting
Association of miR-141 and miR-200c with time to recurrence (TTR) and overall survival (OS) in resected non-small-cell lung cancer (NSCLC) adenocarcinoma (ADC) patients (p).
First Author: Marc Campayo
Poster
2011 ASCO Annual Meeting
Stereotactic body radiation therapy versus high-dose conventional radiation therapy in early-stage NSCLC: A retrospective study on local failure and survival rates.
First Author: S. Jeppesen
Poster
2023 ASCO Annual Meeting
Long-term outcomes of single and five fraction schedules of stereotactic body radiation therapy for early-stage central or peripheral NSCLC: Neither fractionation nor location matter?
First Author: Karen Huang